Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZKAB001 plus nab-paclitaxel and cisplatin as neoadjuvant therapy for esophageal squamous cell carcinoma
CTR20201333Phase 2Active
- Sponsor
- Zhaoke Ophthalmology
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of socazolimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhaoke Ophthalmology. Started Dec 2020; status: active.
02
Drugs
socazolimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20201333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201333.